Crystal forms of crenolanib and methods of use thereof

1. Crystalline Form I of 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1H-benzimidazol-1-yl]-8-quinolinyl]-4-piperidinamine monobenzenesulfonate wherein said crystalline form has a powder x-ray diffraction pattern comprising peaks at diffraction angles (2Θ±0.2) 7.1, 14.8, and 18.2.

2. The crystalline form of claim 1 , wherein the powder x-ray diffraction pattern has peaks at diffraction angles (2Θ±0.2) 7.1, 14.8, 18.2, 24.3 and 26.9.

3. The crystalline form of claim 1 , wherein the powder x-ray diffraction pattern has peaks at diffraction angles (2Θ±0.2) 7.1, 14.8, 16.0, 17.5, 18.2, 24.3, 25.3, and 26.9.

4. The crystalline form of claim 1 , wherein the powder x-ray diffraction pattern has peaks at diffraction angles (2Θ±0.2) 7.1, 14.8, 16.0, 16.8, 17.5, 18.2, 19.7, 21.4, 24.3, 25.3, and 26.9.

5. The crystalline form of claim 1 , wherein the powder x-ray diffraction pattern has peaks at diffraction angles (2Θ±0.2) 7.1, 8.0, 9.6, 11.4, 11.8, 13.9, 14.5, 14.8, 15.5, 16.0, 16.3, 16.8, 17.5, 18.2, 18.7, 19.3, 19.6, 19.7, 20.0, 20.3, 20.9, 21.4, 21.8, 22.6, 24.3, 25.3, 25.9, 26.9, 28.1, 29.5, 29.9, 31.0, 32.3, 33.4, and 34.3.

6. The crystalline form of claim 1 , wherein one or more of (c)-(g) applies:

(c) said crystalline form has a FT-IR spectrum comprising peaks at about 1479, 1271, 1185, 1033, 824, 751, 728, 690, 612, and 564 cm −1 ;

(d) said crystalline form is non-hygroscopic;

(e) said crystalline form has a mass uptake of about 0.9% at 90% RH;

(f) said crystalline form has birefringent, rod-like morphology; and

(g) said crystalline form is substantially pure.

7. A pharmaceutical composition comprising the crystalline form of claim 1 , and a pharmaceutically acceptable carrier.

8. A method of treating a FLT3 mediated proliferative disorder, comprising administering to a subject in need thereof a therapeutically effective amount of the crystalline form of claim 1 , wherein said FLT3 mediated proliferative disorder is selected from the group consisting of Hodgkin's disease, myeloma, acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), chronic neutrophilic leukemia (CNL), acute undifferentiated leukemia (AUL), anaplastic large-cell lymphoma (ALCL), prolymphocytic leukemia (PML), juvenile myelomonocytic leukemia (JMML), adult T-cell ALL, AML with trilineage myelodysplasia (AMLITMDS), mixed lineage leukemia (MLL), myelodysplastic syndromes (MDS), myeloproliferative disorders (MPD), multiple myeloma, biliary tract cancer, bladder cancer, breast cancer, cervical cancer, CNS cancer, colon cancer, colorectal carcinoma, esophageal cancer, gastric cancer, gastroesophageal junction (GEJ) adenocarcinoma, gastric adenocarcinoma, stage IIIB gastric adenocarcinoma, stage IV invasive gastric adenocarcinoma, metastatic esophageal adenocarcinoma, glioblastoma, head and neck cancer, hepatocellular carcinoma, liver cancer, lung cancer, melanoma, non-small cell cancer, nasopharyngeal cancer, neuroendocrine cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, salivary gland cancer, small cell cancer lung cancer, squamous cell cancer, skin cancer, stomach cancer, testicular cancer, thyroid cancer, thymoma, and uterine cancer, or other tumors.

9. A process for the preparation of the crystalline form of claim 1 , comprising suspending 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1H-benzimidazol-1-yl]-8-quinolinyl]-4-piperidinamine monobenzenesulfonate in 1,1-dimethoxymethane or 1-butanol; and then stirring or shaking until precipitation.

10. The method of claim 8 , wherein the FLT-3 mediated proliferative disorder is selected from the group consisting of Hodgkin's disease, myeloma, acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), chronic neutrophilic leukemia (CNL), acute undifferentiated leukemia (AUL), anaplastic large-cell lymphoma (ALCL), prolymphocytic leukemia (PML), juvenile myelomonocytic leukemia (JMML), adult T-cell ALL, AML with trilineage myelodysplasia (AMLITMDS), and mixed lineage leukemia (MLL).

11. The method of claim 8 , wherein the FLT-3 mediated proliferative disorder is selected from the group consisting of myelodysplastic syndromes (MDS), myeloproliferative disorders (MPD), multiple myeloma, biliary tract cancer, bladder cancer, breast cancer, cervical cancer, CNS cancer, colon cancer, colorectal carcinoma, esophageal cancer, gastric cancer, gastroesophageal junction (GEJ) adenocarcinoma, gastric adenocarcinoma, stage IIIB gastric adenocarcinoma, stage IV invasive gastric adenocarcinoma, and metastatic esophageal adenocarcinoma.

12. The method of claim 8 , wherein the FLT-3 mediated proliferative disorder is selected from the group consisting of glioblastoma, head and neck cancer, hepatocellular carcinoma, liver cancer, lung cancer, melanoma, non-small cell cancer, nasopharyngeal cancer, neuroendocrine cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, salivary gland cancer, small cell cancer lung cancer, squamous cell cancer, skin cancer, stomach cancer, testicular cancer, thyroid cancer, thymoma, and uterine cancer.

13. The method of claim 8 , wherein the FLT-3 mediated proliferative disorder is selected from the group consisting of acute myeloid leukemia (AML), breast cancer, colon cancer, colorectal carcinoma, gastric cancer, lung cancer, melanoma, myelodysplastic syndromes (MDS), prostate cancer, and thyroid cancer.

14. The method of claim 8 , wherein the FLT-3 mediated proliferative disorder is selected from the group consisting of acute myeloid leukemia (AML), breast cancer, colon cancer, colorectal carcinoma, gastric cancer, lung cancer, and thyroid cancer.

15. The method of claim 8 , wherein the FLT-3 mediated proliferative disorder is acute myeloid leukemia (AML).

16. The crystalline form of claim 6 , wherein:

(a) said crystalline form has a FT-IR spectrum comprising peaks at about 1479, 1271, 1185, 1033, 824, 751, 728, 690, 612, and 564 cm -1 ;

(b) said crystalline form is non-hygroscopic;

(c) said crystalline form has a mass uptake of about 0.9% at 90% RH;

(d) said crystalline form has birefringent, rod-like morphology; and

(e) said crystalline form is substantially pure.